Recombinant Cynomolgus IFNB1, Fc tagged

• Cat.No.: IFNB1-71C
• Product Overview: Recombinant Cynomolgus IFNB1 (G7NFX1) (Met1-Asn187), fused with the Fc region of mouse IgG at the C-terminus, was produced in Human Cells.

Specification

• Source: Human Cells
• Species: Cynomolgus
• Tag: Fc
• Predicted N Terminal: Met 22
• Form: Lyophilized from sterile PBS, pH 7.4.Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization.
• Molecular Mass: The recombinant cynomolgus IFNB1 is a disulfide-linked homodimer. The reduced monomer comprises 400 amino acids and has a calculated molecular mass of 46.4 KDa.The apparent molecular mass of the protein is approximately 44-49 KDa respectively in SDS-PAGE.
• Endotoxin: < 1.0 eu per μg of the protein as determined by the LAL method.
• Purity: >85 % as determined by SDS-PAGE
• Stability: Samples are stable for up to twelve months from date of receipt at -70oC.
• Storage: Store it under sterile conditions at -20oC~-70oC. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution. Centrifuge the vial at 4℃ before opening to recover the entire contents.
• Protein length: Met1-Asn187

Gene Information

• Gene Name: IFNB1?interferon, beta 1, fibroblast [?Macaca fascicularis?(crab-eating macaque) ]
• Official Symbol: IFNB1
• Gene ID: 102115670
• mRNA Refseq: XM_005581636
• Protein Refseq: XP_005581693
• Chromosome Location: 15

Reviews

06/24/2021

The manufacturer not only ensures the provision of superior protein but also aids researchers with their solid technical support, offering the necessary resources to optimize experimental protocols.

08/29/2020

the IFNB1 protein offers numerous advantages for researchers conducting trials due to its high quality and stability.

11/08/2018

manufacturers or suppliers of proteins can play a crucial role in supporting researchers during trials.

Q&As

Are there any contraindications for IFNB1 treatment?

IFNB1 is generally not recommended for individuals with a history of hypersensitivity to interferons or other components of the drug. It should be used with caution in patients with certain pre-existing medical conditions.

Can IFNB1 be used in cancer treatment?

IFNB1 is being investigated for its potential role in cancer treatment due to its immunomodulatory effects. Clinical trials are ongoing to evaluate its efficacy in various types of cancer.

What are the potential side effects of IFNB1 treatment?

Common side effects include flu-like symptoms, injection site reactions, and changes in blood cell counts. Serious side effects are rare but can include liver problems and allergic reactions.

How is IFNB1 administered in clinical settings?

IFNB1 is often administered through subcutaneous or intramuscular injections. The frequency and dosage depend on the specific condition being treated.

In what other conditions is IFNB1 protein clinically utilized?

IFNB1 is also used in the treatment of certain viral infections, such as hepatitis B and C. It has antiviral properties that can inhibit viral replication.